Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Apr 21. doi: 10.18632/oncotarget.17306. [Epub ahead of print]

2.

Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.

Snaebjornsson P, Jonasson L, Olafsdottir EJ, van Grieken NCT, Moller PH, Theodors A, Jonsson T, Meijer GA, Jonasson JG.

Int J Cancer. 2017 May 6. doi: 10.1002/ijc.30766. [Epub ahead of print]

PMID:
28477390
3.

Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection.

Labots M, van der Mijn JC, Beekhof R, Piersma SR, de Goeij-de Haas RR, Pham TV, Knol JC, Dekker H, van Grieken NCT, Verheul HMW, Jiménez CR.

J Proteomics. 2017 Apr 23. pii: S1874-3919(17)30140-9. doi: 10.1016/j.jprot.2017.04.014. [Epub ahead of print]

PMID:
28442448

Supplemental Content

Loading ...
Support Center